Microfluidic models for adoptive cell-mediated cancer immunotherapies.

[1]  Roger D. Kamm,et al.  Engineering a 3D microfluidic culture platform for tumor-treating field application , 2016, Scientific Reports.

[2]  Roger D. Kamm,et al.  M2a macrophages induce contact-dependent dispersion of carcinoma cell aggregates , 2016 .

[3]  H. Zhang,et al.  Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study , 2016, Tumor Biology.

[4]  A. Ribas,et al.  Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.

[5]  U. Demirci,et al.  Engineering cancer microenvironments for in vitro 3-D tumor models , 2015, Materials today.

[6]  A. Pavesi,et al.  Using microfluidics to investigate tumor cell extravasation and T-cell immunotherapies , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[7]  R. Duarte,et al.  Establishment of a heterotypic 3D culture system to evaluate the interaction of TREG lymphocytes and NK cells with breast cancer. , 2015, Journal of immunological methods.

[8]  Wendell A. Lim,et al.  Remote control of therapeutic T cells through a small molecule–gated chimeric receptor , 2015, Science.

[9]  Roger D. Kamm,et al.  Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment , 2015, Oncotarget.

[10]  J. Thiery,et al.  Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and β2 integrin interactions , 2015, Oncotarget.

[11]  Shuichi Takayama,et al.  Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays. , 2015, Gynecologic oncology.

[12]  R. Childs,et al.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens , 2015, Nature Reviews Drug Discovery.

[13]  H. Tawbi,et al.  Immunotherapeutic Approaches to Sarcoma , 2015, Current Treatment Options in Oncology.

[14]  K. Barbee,et al.  An in vitro model of the tumor-lymphatic microenvironment with simultaneous transendothelial and luminal flows reveals mechanisms of flow enhanced invasion. , 2015, Integrative biology : quantitative biosciences from nano to macro.

[15]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[16]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[17]  R. Kamm,et al.  G04 : Engineered HBV-specific T cells: Disentangling antiviral from killing capacity , 2015 .

[18]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[20]  T. Curiel,et al.  Immunotherapy for Ovarian Cancer , 2015, Current Treatment Options in Oncology.

[21]  A. Bertoletti,et al.  Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. , 2015, Journal of hepatology.

[22]  Henry Du,et al.  Evaluation of photodynamic therapy efficiency using an in vitro three-dimensional microfluidic breast cancer tissue model. , 2015, Lab on a chip.

[23]  D. Beebe,et al.  Microfluidic model of ductal carcinoma in situ with 3D, organotypic structure , 2015, BMC Cancer.

[24]  G. Dubini,et al.  Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation , 2014, Proceedings of the National Academy of Sciences.

[25]  C. Morrison Developers seek to finetune toxicity of T-cell therapies , 2014, Nature Biotechnology.

[26]  J. Clements,et al.  3D Cultures of Prostate Cancer Cells Cultured in a Novel High-Throughput Culture Platform Are More Resistant to Chemotherapeutics Compared to Cells Cultured in Monolayer , 2014, PloS one.

[27]  Roger D Kamm,et al.  A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs. , 2014, Lab on a chip.

[28]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[29]  Lidong Qin,et al.  High-Throughput 3D Cell Invasion Chip Enables Accurate Cancer Metastatic Assays , 2014, Journal of the American Chemical Society.

[30]  F. Belardelli,et al.  A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells , 2014, Journal of immunotoxicology.

[31]  Noo Li Jeon,et al.  A microfluidic platform for quantitative analysis of cancer angiogenesis and intravasation. , 2014, Biomicrofluidics.

[32]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[33]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[34]  D. Beebe,et al.  The present and future role of microfluidics in biomedical research , 2014, Nature.

[35]  P. Wong,et al.  A microfluidic model for organ-specific extravasation of circulating tumor cells. , 2014, Biomicrofluidics.

[36]  G. Dubini,et al.  A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. , 2014, Biomaterials.

[37]  R. Huang,et al.  Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics. , 2014, Biomaterials.

[38]  D. Siegel,et al.  Patient-specific 3D microfluidic tissue model for multiple myeloma. , 2014, Tissue engineering. Part C, Methods.

[39]  H. Abken,et al.  Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma , 2014, Immunological reviews.

[40]  Harjeet Singh,et al.  A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19 , 2014, Immunological reviews.

[41]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[42]  M. Raghunath,et al.  Complementary effects of ciclopirox olamine, a prolyl hydroxylase inhibitor and sphingosine 1-phosphate on fibroblasts and endothelial cells in driving capillary sprouting. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[43]  David J. Beebe,et al.  Understanding the Impact of 2D and 3D Fibroblast Cultures on In Vitro Breast Cancer Models , 2013, PloS one.

[44]  A. Stroock,et al.  Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model. , 2013, Journal of biomedical materials research. Part A.

[45]  K. Eliceiri,et al.  A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. , 2013, Lab on a chip.

[46]  F. Rico,et al.  Cellular capsules as a tool for multicellular spheroid production and for investigating the mechanics of tumor progression in vitro , 2013, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Roger D. Kamm,et al.  Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening , 2013, Advanced healthcare materials.

[48]  R. Kamm,et al.  Mechanisms of tumor cell extravasation in an in vitro microvascular network platform. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[49]  D. Campana,et al.  A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus , 2013, Molecular therapy. Nucleic acids.

[50]  M. Kalos,et al.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.

[51]  B. Shalmon,et al.  Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies , 2013, Clinical Cancer Research.

[52]  Stephen J. Florczyk,et al.  Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells. , 2013, Biomacromolecules.

[53]  R. Jain Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[55]  C. Regenbrecht,et al.  Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? , 2013, Clinical & Experimental Metastasis.

[56]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[57]  R. Huang,et al.  Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[58]  Roger D. Kamm,et al.  Engineering of In Vitro 3D Capillary Beds by Self-Directed Angiogenic Sprouting , 2012, PloS one.

[59]  Stephen J. Florczyk,et al.  3D Porous Chitosan–Alginate Scaffolds: A New Matrix for Studying Prostate Cancer Cell–Lymphocyte Interactions In Vitro , 2012, Advanced healthcare materials.

[60]  R. Kamm,et al.  Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function , 2012, Proceedings of the National Academy of Sciences.

[61]  Jianhua Qin,et al.  A microfluidic-based device for study of transendothelial invasion of tumor aggregates in realtime. , 2012, Lab on a chip.

[62]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[63]  C. Payne,et al.  Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy , 2012, Proceedings of the National Academy of Sciences.

[64]  S. Rosenberg,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[65]  Jian-Long Xiao,et al.  The migration speed of cancer cells influenced by macrophages and myofibroblasts co-cultured in a microfluidic chip. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[66]  A. Bertoletti,et al.  Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.

[67]  Stephen-Mark Cooper,et al.  The effects of time and intensity of exercise on novel and established markers of CVD in adolescent youth , 2011, American journal of human biology : the official journal of the Human Biology Council.

[68]  Francis Lin,et al.  Combinatorial Guidance by CCR7 Ligands for T Lymphocytes Migration in Co-Existing Chemokine Fields , 2011, PloS one.

[69]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[70]  K. Pienta,et al.  Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. , 2009, Biomaterials.

[71]  Ivan Martin,et al.  New dimensions in tumor immunology: what does 3D culture reveal? , 2008, Trends in molecular medicine.

[72]  J. Aerts,et al.  Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics , 2007, Gene Therapy.

[73]  L. Terracciano,et al.  Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes , 2007, British Journal of Cancer.

[74]  H. Levitsky,et al.  Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance1 , 2007, The Journal of Immunology.

[75]  O. Singer,et al.  Use of Amplicon-6 Vectors Derived from Human Herpesvirus 6 for Efficient Expression of Membrane-Associated and -Secreted Proteins in T Cells , 2004, Journal of Virology.

[76]  A. Lawson,et al.  Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain , 2004, The Journal of Immunology.

[77]  Martin Fussenegger,et al.  Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. , 2003, Biotechnology and bioengineering.

[78]  Pierre Validire,et al.  Impact of human bladder cancer cell architecture on autologous T‐lymphocyte activation , 2002, International journal of cancer.

[79]  A. Mikos,et al.  A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. , 2016, Biomaterials.

[80]  Z. Ren,et al.  Screening candidate metastasis-associated genes in three-dimensional HCC spheroids with different metastasis potential. , 2014, International journal of clinical and experimental pathology.

[81]  R. Brentjens with Chemotherapy-Refractory Acute Lymphoblastic Leukemia CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults , 2013 .